Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kendra Sweet

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid LeukemiaKendra Sweet, Rami Komrokji, Eric Padron, et al.
Leukemia Research|July 30, 2019
Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)Seongseok Yun, Rohit Sharma, Onyee Chan, et al.
Leukemia Research|December 21, 2022
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patientsSomedeb Ball, Luis E Aguirre, Akriti G Jain, et al.
American Journal of Hematology|September 14, 2023
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemiaParth C Patel, Somedeb Ball, Akriti G Jain, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2021
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid MalignanciesQuinto J Gesiotto, David M Swoboda, Rory M Shallis, et al.
Transplantation and Cellular Therapy|August 15, 2024
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic SyndromesOmar Albanyan, Hany Elmariah, Denise Kalos, et al.
Blood|December 9, 2022
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemiaAmanda Przespolewski, Aaron D Goldberg, Chetasi Talati, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 1, 2024
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell TransplantFilip Ionescu, Jerel C David, Apoorva Ravichandran, et al.
The Lancet. Haematology|March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion studyGuillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Blood Advances|January 3, 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AMLOnyee Chan, Najla Al Ali, Hammad Tashkandi, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid LeukemiaKendra Sweet, Rami Komrokji, Eric Padron, et al.
Leukemia Research|July 30, 2019
Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)Seongseok Yun, Rohit Sharma, Onyee Chan, et al.
Leukemia Research|December 21, 2022
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patientsSomedeb Ball, Luis E Aguirre, Akriti G Jain, et al.
American Journal of Hematology|September 14, 2023
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemiaParth C Patel, Somedeb Ball, Akriti G Jain, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2021
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid MalignanciesQuinto J Gesiotto, David M Swoboda, Rory M Shallis, et al.
Transplantation and Cellular Therapy|August 15, 2024
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic SyndromesOmar Albanyan, Hany Elmariah, Denise Kalos, et al.
Blood|December 9, 2022
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemiaAmanda Przespolewski, Aaron D Goldberg, Chetasi Talati, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 1, 2024
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell TransplantFilip Ionescu, Jerel C David, Apoorva Ravichandran, et al.
The Lancet. Haematology|March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion studyGuillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Blood Advances|January 3, 2024
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AMLOnyee Chan, Najla Al Ali, Hammad Tashkandi, et al.
Pageof 9